Carlsmed Q3 sales jump 65% on surgeon user growth, raises FY revenue guidance
CARL•Carlsmed’s third-quarter revenue rose 65% year over year to $21.6 million, and it raised its 2026 revenue guidance to $78 million-$80 million. Its adjusted EBITDA loss narrowed to $7.3 million from $8.2 million a year earlier.
1. Revenue and outlook
Carlsmed said third-quarter revenue increased 65% year over year to $21.6 million, while its adjusted EBITDA loss narrowed to $7.3 million from $8.2 million. The company raised its full-year 2026 revenue guidance to $78 million-$80 million.
2. Growth drivers
Carlsmed said its surgeon user base grew more than 60% year over year. It cited new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure and the launch of its aprevo Lumbar Bi-lateral Posterior System, which targets about 30,000 U.S. lumbar fusion procedures annually. The company expects CMS reimbursement changes to support growth in 2027.
